Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Karo Bio, Wyeth enter inflammation collaboration
December 2008
SHARING OPTIONS:

STOCKHOLM—Karo Bio and Wyeth Pharmaceuticals have entered a drug discovery collaboration focused on the liver X receptor (LXR) as a pharmaceutical target. LXR is a new member of the nuclear receptor protein family and the receptor plays important roles in cholesterol metabolism and inflammatory responses. The collaboration is primarily focused on atherosclerosis but other opportunities have also been explored.

"Our collaboration with Wyeth has generated numerous compound series and a deepened understanding about LXR function in disease processes," says Per Olof Wallström, president of Karo Bio. "Recently is has been shown that LXR is an important target for treatment of inflammatory disorders, and we see exciting opportunities in the continued collaboration." DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.